Enterprise Value
314.4M
Cash
98.72M
Avg Qtr Burn
-14.16M
Short % of Float
0.02%
Insider Ownership
6.96%
Institutional Own.
0.19%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Buparlisib/AN2025 + Paclitaxel Details Cancer, Head and neck squamous cell carcinoma | Phase 3 Data readout | |
Buparlisib/AN2025 in comb w/chemoradiotherapy and radiotherapy Details Cancer, Rectal cancer | Phase 2 Data readout | |
AN0025 + definitive chemoradiotherapy (dCRT) Details Cancer, Esophageal cancer | Phase 1b Data readout |